Possibilities for monitoring the pharmacodynamics of dabigatran etexilate
https://doi.org/10.25789/YMJ.2021.76.11
Abstract
The sensitivity and prognostic value of laboratory tests and methods for assessing pharmacodynamics in relation to the system of regulation of the aggregate state of blood after a single dose of dabigatran etexilate at a dosage of 150 mg were investigated.
According to the results of LPTEG, the maximum severity of the direct pharmacodynamic effect of dabigatran etexilate was recorded at the 4th hour after taking the drug, which was reflected by a pronounced decrease in the efficiency of the proteolytic stage of fibrinogenesis, with the return of the activity of the proteolytic stage of fibrinogenesis to the initial level at the 8th hour with the preservation of residual antithrombotic activity up to 12 hours.
The use of thromboelastography was limited to a 4-hour interval, while the ACTV test was limited to 2 hours from the moment of taking the drug, after which the level of indicators returned to the initial value.
About the Authors
M. A. Solovyev
Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg Tomsk NIMC RAS
Russian Federation
Russian Federation
Solovyov Maxim Alexandrovich – Candidate of Medical Sciences, PhD
D. A. Momot
Altai State Medical University
Russian Federation
Russian Federation
Momot Dmitry Andreevich – student
Barnaul
L. Y. Kotlovskaya
Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg Tomsk NIMC RAS
Russian Federation
Russian Federation
Kotlovskaya Larisa Yuryevna – Candidate of Medical Sciences
I. I. Tyutrin
Siberian State med. University
Russian Federation
Russian Federation
Tyitrin Ivan Illarionovich – MD, Professor
Tomsk
V. V. Udut
Research Institute of Pharmacology and Regenerative Medicine named after E.D. Goldberg Tomsk NIMC RAS
Russian Federation
Russian Federation
Udut Vladimir V. – MD, Prof., Corresponding Member of the Russian Academy of Sciences, Head of the Lab.
References
1. Tyutrin II, Udut VV. Low-frequency piezothromboelastography of whole blood: algorithms for the diagnosis and correction of hemostasiological disorders. Publishing House of Tomsk State University. 2016: 170.
2. Udut VV., Tyutrin II., Solovyev MA. Realities and prospects of global tests in assessing the functional state of the pro- and anticoagulant system. Bulletin of Experimental Biology and Medicine. 2015; 159 (2): 162-165.
3. Udut VV, Tyutrin II, Solovyev MA. Low-frequency piezothromboelastography technology in monitoring anti-thrombotic therapy. Experimental and Clinical Pharmacology 2017; 80 (11): 10-17. DOI: 10.30906/0869-2092-2019-82-7-10-13
4. Albaladejo P., Pernod G., Godier A. Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016. Anaesth Crit Care Pain Med. 2018;37(4):391-399. DOI: 10.1016/j.accpm.2018.04.009
5. Cano E.L., Miyares M.A. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10(2):160-163. DOI: 10.1016/j.amjopharm.2012.02.004
6. Chen B.C., Viny A.D., Garlich F.M. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila). 2012;50(9):854-857. DOI: 10.3109/15563650.2012.721888
7. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670. Published 2014 Jul 23. DOI: 10.1136/bmj.g4670
8. Eikelboom J.W., Connolly S.J., Brueckmann M. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-1214. DOI: 10.1056/NEJMoa1300615.
9. Gosselin R.C., Adcock D.M. The laboratory's 2015 perspective on direct oral anticoagulant testing [published correction appears in J Thromb Haemost. 2019 Apr;17(4):698]. J Thromb Haemost. 2016;14(5):886-893. DOI: 10.1111/jth.13266
10. Gosselin R.C., Douxfils J. Ecarin based coagulation testing. Am J Hematol. 2020;95(7):863-869. DOI: 10.1002/ajh.25852
11. Hernandez I., Baik S.H., Piñera A., Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation [published correction appears in JAMA Intern Med. 2018 Dec 1;178(12):1732]. JAMA Intern Med. 2015;175(1):18-24. DOI: 10.1001/jamainternmed.2014.5398
12. https://www.boehringer-ingelheim.ru/sites/ru/files/files/pradaxa_150_mg_19-08-2020.pdf
13. Jelliffe R., Christians U. The New Direct-Acting Oral Anticoagulants Need to be Monitored!. Ther Drug Monit. 2020;42(3):357-359. DOI: 10.1097/FTD.0000000000000745
14. Kim J., Jang H.J., Schellingerhout D. Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State. Ann Neurol. 2021;89(3):444-458. DOI: 10.1002/ana.25964
15. Romiti G.F., Corica B., Proietti M. A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. Future Cardiol. 2021;17(2):215-226. DOI: 10.2217/fca-2020-0084
16. Solbeck S., Ostrowski S.R., Stensballe J., Johansson P.I. Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests. Int J Cardiol. 2016;208:14-18. DOI: 10.1016/j.ijcard.2016.01.148
17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295. DOI: 10.2165/00003088-200847050-00001
18. Wigle P., Hein B., Bernheisel C.R. Anticoagulation: Updated Guidelines for Out-patient Management. Am Fam Physician. 2019;100(7):426-434.
19. Wychowski M.K., Kouides P.A. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):e10. DOI: 10.1345/aph.1Q747
Review
For citations:
Solovyev M.A., Momot D.A., Kotlovskaya L.Y., Tyutrin I.I., Udut V.V. Possibilities for monitoring the pharmacodynamics of dabigatran etexilate. Yakut Medical Journal. 2021;(4):47-51. https://doi.org/10.25789/YMJ.2021.76.11
Views:
13
Email this article 